drugset / Trial / NCT01777776

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

NCT01777776

Phase 1/2 Terminated 28 enrolled Array BioPharma
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability and efficacy of LEE011 and LGX818 when administered orally to patients with BRAF mutant melanoma.

Timeline

Start
2013-07
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Encorafenib Small molecule Oral
Subject Ribociclib Small molecule Oral

Indications